Mikayla Paolini's practice focuses on litigation and investigations in the health care and life sciences sectors. She has experience representing pharmaceutical companies and academic medical centers in lawsuits related to oncology, cardiology, immunology, organ transplantation, prenatal testing, and opioid use disorder. Recently, Mikayla helped secure a total defense verdict in Kentucky state court, defeating a multibillion dollar fraud claim.
She also has experience in class action cases, including a federal securities class action lawsuit. She has handled investigations before the FTC (Federal Trade Commission), DOJ (Department of Justice), OIG (Office of Inspector General), and state medical boards. On the regulatory side, her practice involves counseling clients on digital health concerns, such as prescribing constraints, provider licensure, and remote supervision. Mikayla also counsels clients in the life sciences sector regarding compliance with the Federal Food, Drug, and Cosmetic Act (FD&C Act).
Mikayla maintains an active pro bono practice. She participates in Jones Day's VetLex initiative, representing veterans appealing disability benefit decisions, and the Her Justice initiative, representing local women in U visa and Violence Against Women Act petitions.
Mikayla is a member of the New York Office's Women’s Initiative and the Associates Committee.
经验
- Emory University (J.D. with honors 2019; Notes & Comments Editor, Emory Law Journal; Master of Bioethics 2019); Centre College (B.A. in Philosophy summa cum laude 2016; Phi Beta Kappa; John C. Young Scholar)
- New York and U.S. District Courts for the Southern and Eastern Districts of New York
- Extern to Judge Frank M. Hull, U.S. Court of Appeals, Eleventh Circuit (Fall 2019)
发送前请注意
*Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice